Efficacy of ICD in ischemic cardiac disease determined by reconstructing patient-level data from Kaplan-Meier survival curves ICD in patients with ischemic cardiac disease
Article Sidebar
Downloads
Submit your own article
Register as an author to reserve your spot in the next issue of the Medical Research Archives.
Author RegistrationJoin the Society
The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.
Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.
MembershipMain Article Content
Abstract
Background: Implantable cardioverter defibrillators (ICDs) are indicated for the prevention of sudden death in ischemic heart disease. Four randomized trials are the main source of efficacy data.
Aims and Methods: Reconstruction of patient-level data from survival curves is a new technique (called the Shiny method or IPDfromKM method) for studying effectiveness. We used this method to analyze the four afore-mentioned trials based on the endpoint of all-cause mortality. After reconstruction by the IPDfromKM method, patient-level data were pooled according to three therapeutic options: ICDs, medical therapy, and no active treatment. Standard statistical comparisons were then made between these three groups of patients. Time-to-event data for reconstructed patients were evaluated using standard Kaplan-Meier analysis. The hazard ratio was estimated to compare and interpret these survival data.
Results: A total of 4,621 patients were enrolled (follow-up, 60 months). Of these, 1,827 were treated with ICDs and 1,493 received medical therapy; the control group included 1,301 patients who received no active treatment. Our analysis, based on pooled Kaplan-Meier curves, showed that ICD was the most effective, followed by medical therapy and no active treatment. ICD was associated with significantly better survival compared with medical therapy (hazard ratio, 0.6523; 95% confidence interval [CI], 0.5580 to 0.7622; p<0.001) and no active treatment (hazard ratio, 0.6340; 95%CI, 0.5417 to 0.7424; p<0.001). In the subgroup of patients receiving an ICD, the heterogeneity between trials was negligible, whereas it was significant in the subgroups receiving medical therapy or no active treatment.
Conclusions: Our results provide original evidence on long-term survival in ischemic heart disease. Methodologically, our study confirmed the advantages of the Shiny method.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Knops RE, Olde-Nordkamp LR, Delnoy PH, et al. Subcutaneous or Transvenous Defibrillator Therapy (PRAETORIAN). N Engl J Med. 2020; 383(6):526-536.
3. Wolf S, Götz G, Wernly B, Wild C. Subcutaneous implantable cardioverter- defibrillator: a systematic review of comparative effectiveness and safety. ESC Heart Fail. 2023; 10(2):808-823.
4. Tfelt-Hansen J, Garcia R, Albert C, et al. Risk stratification of sudden cardiac death: a review. Europace. 2023;25(8):euad203.
5. Moss AJ, Hall J, Cannom DS, et al. (1996) Improved survival with an implanted cardioverter-defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1335:1933–1940.
6. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 1999;341:1882–1890. https://doi.org/10.1056/nejm199912163412503
7. Moss AJ, Zareba W, Hall J. et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883.
8. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237.
9. Hess PL, Laird A, Edwards R., et al. Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. Heart Rhythm 2013;10(6):828-35.
10. Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21(1):111. doi: 10.1 186/s12874-021-01308-8.
11. Messori A, Damuzzo V, Rivano M, et al. Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses. Cancers (Basel). 2023;1 5(6):1633. doi: 10.3390/cancers15061633.
12. Messori A. Reconstruction of individual-patient data from the analysis of Kaplan-Meier curves: the use of this method has extended from oncology to cardiology (preprint). Open Science Framework, 2023;doi 10.17605/OSF.I O/4XDGR, published 20 August 2023, url https://osf.io/qejus ,accessed 21 August 2023
13. Damuzzo V, Agnoletto L, Leonardi L, Chiumente M, Mengato D, Messori A. Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors. Front Oncol. 2019;9: 453. doi: 10.3 389/fonc.2019.00453.
14. R Core Team. Foundation for Statistical Computing, Vienna, Austria, 2021, url https://www.R-project.org/
15. Woodford R, Zhou D, Kok PS, et al. Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials. JCO Precis Oncol. 2024;8:e2300296. doi: 10.1200/PO.23.00296. PMID: 38207226.
16. Masuda Y, Yeo MHX, Syn NL, Goh BKP, Koh YX. Surgery for liver metastases from primary breast cancer: A reconstructed individual patient data meta-analysis. Eur J Surg Oncol. 2024;50(1):107277. doi: 10.1016/ j.ejso.2023.107277.
17. Chen D, Guo J, Huang H, Tian L, Xie Y, Wu Q. Prognostic value of circulating tumor DNA in operable non-small cell lung cancer: a systematic review and reconstructed individual patient-data based meta-analysis. BMC Med. 2023;27;21(1):467. doi: 10.1186/s 12916-023-03181-2.
18. Wang, B.C., Fu, C., Lin, G.H. (2023) The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data. Front Immunol. 14:1185577. doi: 10.338 9/fimmu.2023.1185577.
19. Everest, L., Blommaert, S., Tu D., et al. (2022) Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group. Value Health. 25(7):1157-1164. doi: 10.1016/j.jval.2021.12.004.